Gilead Sciences (NASDAQ:GILD) PT Lowered to $73.00

Gilead Sciences (NASDAQ:GILD) had its price target decreased by investment analysts at Credit Suisse Group from $75.00 to $73.00 in a research report issued to clients and investors on Friday, BenzingaRatingsTable reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective would indicate a potential upside of 4.99% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $97.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 21st. Piper Sandler reaffirmed a “buy” rating and set a $90.00 price target on shares of Gilead Sciences in a research note on Monday, June 8th. Cantor Fitzgerald lifted their price target on shares of Gilead Sciences from $78.00 to $86.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 7th. DZ Bank reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Monday, June 15th. Finally, Raymond James cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating in a research report on Friday, May 1st. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $79.63.

Gilead Sciences stock opened at $69.53 on Friday. The company’s 50-day moving average price is $75.47 and its 200-day moving average price is $73.57. Gilead Sciences has a twelve month low of $60.89 and a twelve month high of $85.97. The company has a quick ratio of 2.92, a current ratio of 3.04 and a debt-to-equity ratio of 1.00. The company has a market cap of $87.22 billion, a PE ratio of -289.70, a price-to-earnings-growth ratio of 2.34 and a beta of 0.70.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.46). Gilead Sciences had a positive return on equity of 32.17% and a negative net margin of 1.16%. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.24 billion. As a group, sell-side analysts expect that Gilead Sciences will post 6.79 earnings per share for the current fiscal year.

In related news, Director John Francis Cogan sold 2,416 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $81.75, for a total transaction of $197,508.00. Following the completion of the transaction, the director now owns 57,276 shares in the company, valued at approximately $4,682,313. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Brett A. Pletcher sold 13,210 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the transaction, the executive vice president now owns 27,204 shares of the company’s stock, valued at approximately $2,155,372.92. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,079 shares of company stock valued at $2,240,630. 0.13% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Capital Research Global Investors raised its stake in shares of Gilead Sciences by 12.7% during the 1st quarter. Capital Research Global Investors now owns 95,982,319 shares of the biopharmaceutical company’s stock worth $7,175,643,000 after acquiring an additional 10,849,434 shares in the last quarter. Capital International Investors increased its stake in Gilead Sciences by 336.8% during the 1st quarter. Capital International Investors now owns 56,369,657 shares of the biopharmaceutical company’s stock valued at $4,214,200,000 after purchasing an additional 43,464,551 shares in the last quarter. Capital World Investors increased its stake in Gilead Sciences by 123.0% during the 1st quarter. Capital World Investors now owns 46,331,318 shares of the biopharmaceutical company’s stock valued at $3,463,732,000 after purchasing an additional 25,555,467 shares in the last quarter. Geode Capital Management LLC increased its stake in Gilead Sciences by 3.4% during the 1st quarter. Geode Capital Management LLC now owns 19,882,508 shares of the biopharmaceutical company’s stock valued at $1,484,311,000 after purchasing an additional 658,471 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in Gilead Sciences by 2.6% during the 1st quarter. Legal & General Group Plc now owns 8,496,358 shares of the biopharmaceutical company’s stock valued at $634,826,000 after purchasing an additional 216,005 shares in the last quarter. Hedge funds and other institutional investors own 78.74% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Read More: Why is the ex-dividend date different from the record date?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.